Memorial Sloan Kettering Cancer Center
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- Radiation: Stereotactic Body Radiation Therapy (SBRT)
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT02684253
- Locations
- πΊπΈ
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
πΊπΈMemorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
Negative Pressure Wound Therapy in Post-Operative Incision Management
- Conditions
- Negative-Pressure Wound Therapy
- Interventions
- Other: dry gauzeDevice: The Prevena Incision Management System
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 583
- Registration Number
- NCT02682316
- Locations
- πΊπΈ
Lehigh Valley Health Network, Allentown, Pennsylvania, United States
πΊπΈMemorial Sloan Kettering Commack (Consent and Follow-Up only), Commack, New York, United States
πΊπΈMemorial Sloan Kettering Nassau (Consent and Follow-Up only), Uniondale, New York, United States
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
- Conditions
- RelapsedAcute LeukemiaNewly Diagnosed
- Interventions
- Other: assessments
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 1365
- Registration Number
- NCT02677064
- Locations
- πΊπΈ
Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States
πΊπΈLehigh Valley Health Network, Allentown, Pennsylvania, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
- Conditions
- Solid Tumor CancersBladder CancerLung CancerUrinary Tract Cancers
- Interventions
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 131
- Registration Number
- NCT02675829
- Locations
- πΊπΈ
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
πΊπΈMemorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
πΊπΈMemorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT02673333
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈUniversity of Michigan (Data or Specimen Analysis Only), Ann Arbor, Michigan, United States
Pilot Trial of Homebound Stem Cell Transplantation
- Conditions
- Plasma Cell Dyscrasia
- Interventions
- Behavioral: Home monitoring teleconsult visitsBehavioral: Patient Reported Outcomes (PRO)Behavioral: Caregiver Reported Outcomes instruments
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 91
- Registration Number
- NCT02671448
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Prospective Registry of Multiplex Testing (PROMPT)
- Conditions
- Genetic Testing
- Interventions
- Other: saliva specimenBehavioral: questionnaire
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 689
- Registration Number
- NCT02665195
- Locations
- πΊπΈ
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
πΊπΈUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈMemorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
- Conditions
- GliomaRecurrent Malignant Glioma
- Interventions
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT02658279
- Locations
- πΊπΈ
Memorial Sloan Kettering Westchester, Harrison, New York, United States
πΊπΈMemorial Sloan Kettering Commack, Commack, New York, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
- Conditions
- Bladder CancerNon-Muscle-Invasive Urothelial Carcinoma
- Interventions
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT02657486
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Single-agent Cobimetinib for Adults With Histiocytic Disorders
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT02649972
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈMayo Clinic, Rochester, Minnesota, United States